SCYNEXIS Raises $40mln in Private Placement to Fund ADPKD Therapy Development

SCYNEXIS, a biotechnology company, has announced a $40 million private placement with institutional and accredited investors, with the option to raise an additional $52.2 million. The company will issue 34.75 million common shares, 8.75 million pre-funded warrants, and accompanying common warrants. The financing includes participation from new and existing institutional investors, including Great Point Partners and Squadron Capital Management.